Fjarde Ap-fonden’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21.4M | Sell |
39,450
-1,080
| -3% | -$608K | 0.1% | 181 |
|
|
2026
Q1 | $24M | Buy |
40,530
+12,650
| +45% | +$6.3M | 0.13% | 151 |
|
|
2025
Q4 | $13.6M | Buy |
27,880
+380
| +1% | +$177K | 0.11% | 166 |
|
|
2025
Q3 | $11.5M | Sell |
27,500
-7,600
| -22% | -$2.56M | 0.1% | 200 |
|
|
2025
Q2 | $10.1M | Buy |
35,100
+6,000
| +21% | +$1.79M | 0.09% | 207 |
|
|
2025
Q1 | $8.97M | Buy |
29,100
+5,800
| +25% | +$1.99M | 0.11% | 190 |
|
|
2024
Q4 | $8.22M | Buy |
23,300
+1,900
| +9% | +$698K | 0.08% | 233 |
|
|
2024
Q3 | $7.67M | Buy |
+21,400
| New | +$7.23M | 0.08% | 249 |
|
|
2024
Q1 | $2.48M | Buy |
10,800
+200
| +2% | +$45.1K | 0.03% | 473 |
|
|
2023
Q4 | $2.33M | Buy |
10,600
+1,900
| +22% | +$438K | 0.03% | 482 |
|
|
2023
Q3 | $1.97M | Sell |
8,700
-100
| -1% | -$23K | 0.03% | 488 |
|
|
2023
Q2 | $1.94M | Buy |
8,800
+1,000
| +13% | +$222K | 0.02% | 492 |
|
|
2023
Q1 | $1.75M | Buy |
+7,800
| New | +$1.92M | 0.02% | 467 |
|
|
2019
Q2 | – | Sell |
-13,036
| Closed | -$1.53M | – | 622 |
|
|
2019
Q1 | $1.53M | Buy |
13,036
+1,295
| +11% | +$151K | 0.02% | 563 |
|
|
2018
Q4 | $1.28M | Sell |
11,741
-3,200
| -21% | -$371K | 0.02% | 546 |
|
|
2018
Q3 | $1.91M | Hold |
14,941
| – | – | 0.03% | 569 |
|
|
2018
Q2 | $1.69M | Buy |
14,941
+1,437
| +11% | +$158K | 0.03% | 586 |
|
|
2018
Q1 | $1.52M | Sell |
13,504
-400
| -3% | -$50.8K | 0.02% | 596 |
|
|
2017
Q4 | $2.06M | Buy |
13,904
+1,040
| +8% | +$132K | 0.03% | 566 |
|
|
2017
Q3 | $1.51M | Buy |
12,864
+100
| +0.8% | +$12.8K | 0.03% | 572 |
|
|
2017
Q2 | $1.66M | Buy |
12,764
+2,025
| +19% | +$253K | 0.03% | 563 |
|
|
2017
Q1 | $1.45M | Sell |
10,739
-1,056
| -9% | -$160K | 0.03% | 553 |
|
|
2016
Q4 | $1.69M | Sell |
11,795
-1,528
| -11% | -$195K | 0.04% | 532 |
|
|
2016
Q3 | $1.57M | Sell |
13,323
-138
| -1% | -$16.6K | 0.03% | 547 |
|
|
2016
Q2 | $1.43M | Sell |
13,461
-681
| -5% | -$76K | 0.03% | 554 |
|
|
2016
Q1 | $1.58M | Buy |
14,142
+1,386
| +11% | +$175K | 0.04% | 540 |
|
|
2015
Q4 | $2M | Sell |
12,756
-237
| -2% | -$34.5K | 0.05% | 439 |
|
|
2015
Q3 | $1.71M | Sell |
12,993
-500
| -4% | -$80.2K | 0.05% | 480 |
|
|
2015
Q2 | $2.35M | Buy |
+13,493
| New | +$2.43M | 0.06% | 415 |
|
Other funds holding UTHR
ACA
JT
Fjarde Ap-fonden's UTHR Position: Q2 2026 in Review
Fjarde Ap-fonden reduced its United Therapeutics (UTHR) stake by 2.7% in Q2 2026, selling an estimated $608K and leaving 39,450 shares worth $21.4M. The position accounts for 0.1% of the portfolio, ranked #181.
Fjarde Ap-fonden first reported a position in UTHR in Q2 2015 and has held it in 29 quarters since. The position peaked at $24M in Q1 2026. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Fjarde Ap-fonden held 39,450 shares of United Therapeutics worth $21.4M as of Q2 2026.
- Fjarde Ap-fonden sold 1,080 United Therapeutics shares in Q2 2026, an estimated $608K.
- United Therapeutics made up 0.1% of Fjarde Ap-fonden's portfolio in Q2 2026, its #181 holding.
- Fjarde Ap-fonden first reported a position in United Therapeutics in Q2 2015 and has held it in 29 quarters since.
- Fjarde Ap-fonden's United Therapeutics position peaked at $24M in Q1 2026.
- 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Fjarde Ap-fonden's 13F filing for Q2 2026, filed 29 Jul 2026.